TITLE

pharmaceuticals & fine chemicals

PUB. DATE
October 2005
SOURCE
Chemical Week;10/26/2005, Vol. 167 Issue 35, p34
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents an update on the pharmaceutical industry as of October 26, 2005. Purchase of the generic drugs operations of Alpharma by generic drugs firm Actavis Group; Decision of biotechnology manufacturer Progenitor Cell Therapy to manufacture Cellerant Therapeutics' stem cell drug candidate CLT-001.
ACCESSION #
18733006

 

Related Articles

  • Actavis bids on Alpharma unit.  // Chemical Market Reporter;10/24/2005, Vol. 268 Issue 14, p4 

    Reports on the cash deal between Actavis Group company and Alpharma Inc. in Reykjavik, Iceland. Value of the transaction; Significance of the acquisition of Alpharma on the U.S. market position of Actavis; Terms and conditions of the deal.

  • Full steam ahead for Actavis in generics.  // Chemical Market Reporter;7/17/2006, Vol. 270 Issue 2, p24 

    The article announces that Iceland-based Actavis is pushing through with its generic pharmaceuticals business in its attempt to attain a leading position in the worldwide generic drug industry. Actavis now sells dantrolene and isradipine in the United States. It also markets amantadine,...

  • Actavis to Build Three Plants in India; Opens Laboratories. Ramesh, Deepti // Chemical Week;11/3/2008, Vol. 170 Issue 34, p31 

    The article reports on the announcement by generics pharmaceutical manufacturer Actavis that it is building three pharmaceutical plants in India. It broke ground on a pilot plant and an active pharmaceutical ingredient (API) plant at the company's existing API facility at Alathur, in southern...

  • Actavis acquires bulk drugs unit of Sanmar Speciality.  // Chemical Business;Mar2007, Vol. 21 Issue 3, p78 

    The article reports that Actavis has taken over the bulk drugs division of Chennai, India-based Sanmar Specialty Chemicals Ltd. In December 2006, Actavis had taken over Gradix Pharmaceuticals, a tablets manufacturer also in Chennai. With the acquisition of Sanmar, Actavis had not only captured...

  • Actavis Expands into New Markets; May Enter Biosimilars. Ramesh, Deepti // Chemical Week;10/26/2009, Vol. 171 Issue 26, p31 

    The article reports on the decision of generic pharmaceuticals producer Actavis to expand its operations in other regions. According to Stefan Sveinsson, executive vice president of Actavis, the company is planning to enter the biosimilars market through joint ventures and partnerships....

  • Fast-rising generics producer breaks ice in the US via merger. Jarvis, Lisa // Chemical Market Reporter;5/30/2005, Vol. 267 Issue 22, p35 

    Reports that Actavis Group based in Reykjavik, Iceland, has improved its financial performance by making good on a long-standing goal of penetrating the U.S. market in the generic pharmaceuticals arena. Total revenue of the company in 2004; Number of products sold in the U.S. market for...

  • Established Presence.  // Retail Merchandiser;Nov/Dec2009, Vol. 49 Issue 6, p128 

    The article explores how Actavis Group, a generic pharmaceutical manufacturer successfully entered the U.S. market and established Actavis Inc. The company is ranked fifth in terms of size among the world's generic pharmaceutical manufacturers. It relates how Actavis' acquisitions of Amide...

  • pharmaceuticals & fine chemicals.  // Chemical Week;1/3/2007, Vol. 169 Issue 1, p31 

    The article presents updates on companies in the industry of pharmaceuticals and fine chemicals. Actavis Group has acquired a manufacturing plant from Grandix Pharmaceuticals. Lonza has agreed to license its glutamine synthetase expression system and GS-CHO protein free system to Roche for the...

  • Scil Proteins to Manufacture Reteplase for Actavis.  // Biomedical Market Newsletter;1/21/2012, Vol. 21, p1 

    The article reports on the manufacturing of reteplase by the biotec company Scil Proteins for the generic pharmaceutical group of companies Actavis Group hf. The manufacturing of the recombinant protein in the medicinal product rapilysin that is required for the thrombolytic treatment of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics